Last reviewed · How we verify
NCT04972279
Precision Assignment of Intervention Messages to Promote Physical Activity - Precision AIM
Phase 1, PHASE2 trial testing Digital message (text + image) in Cardiovascular Risk Factor in 80 participants. Status unknown.
15 December 2022
Quick facts
| Lead sponsor | Penn State University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 2 January 2022 |
| Primary completion | 15 December 2022 |
| Estimated completion | 15 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Digital message (text + image)
Conditions studied
- Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →
Sponsor
Penn State University
Who can join
Adults 18 to 29, any sex, with Cardiovascular Risk Factor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our goal is to develop personalized decision rules for selecting the frequency, timing, and content of messages to promote physical activity. The objective of this project is to evaluate the acceptability and feasibility of two strategies for calibrating decision rules used to send those messages. Participants will wear an activity monitor for the collection of PA data and be randomly assigned to one of two adaptive intervention strategies. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions. Our hypothesis is that more intensive intervention strategies will offer a better user experience because the resulting treatments will be experienced as more personalized.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04972279
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Risk Factor
Currently open trials in the same condition.
- NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
- NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
- NCT06372054 — TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models · recruiting
- NCT05887622 — The Potassium Supplementation Study · NA · recruiting
- NCT04962061 — A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors. · NA · recruiting
Other Penn State University trials
Trials by the same sponsor.
- NCT07147387 — Lions Hearts: A Community Approach to Multigenerational Cardiovascular Disease Risk · NA · not yet recruiting
- NCT07266506 — Development of an Eating Behavior Risk Score · NA · not yet recruiting
- NCT07229781 — Mediterranean Diet and Blood Sugar Study · NA · not yet recruiting
- NCT07235358 — Cardiometabolic Effects of Pecan Snacking in Prediabetes · NA · not yet recruiting
- NCT06823518 — Thrive Initiative Parent-Education Programming Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04972279 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Penn State University
- Last refreshed: 10 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972279.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing